Navigation Links
Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments

Scientists in the United States have tested all possible pairings of the 100 cancer drugs approved for use in patients in order to discover whether there are any combinations not tried previously that are effective in certain cancers.

Dr Susan Holbeck (PhD), a biologist in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute (USA) will tell the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Wednesday) that she and her colleagues have completed testing the 100 drugs, with 300,000 experiments to test the 5000 possible drug combinations in a panel of 60 cell lines developed by the National Cancer Institute (NCI-60 panel). "The goal is to identify novel drug combinations that are more active than the single agents alone. Since these are all approved agents, there is the potential to rapidly translate these combinations into the clinic," she will say.

Cancer treatments often use a combination of drugs, as a single drug rarely produces a long-lasting response due to the cancer becoming drug resistant. Some drug combinations have evolved over time by incorporating new agents into existing standards of care, while many newer treatments try to select combinations of drugs that target particular pathways that are known to be involved in the development of the cancer. However, some combinations can be so toxic that they have to be used at lower doses that may not be effective against the cancer.

"In addition, there are a large number of drug combinations that have never been used together in people, and for which there is no experimental information on whether there might a benefit to the combination," said Dr Holbeck. "We decided that it would be a feasible project to generate experimental data for all 5000 possible combinations of pairs, and that we would make these data available to all to enable additional experiments in support of taking new combinations to clinical trials.

"In order to provide a resource for understanding the efficacy of drug combinations, we have undertaken a systematic screening of most small molecule oncology drugs approved in the US, each in combination with all the others. This was done using a panel of human tumour cell lines derived from nine different types of cancer.

"We chose to test the combinations in the NCI-60 panel a group of diverse cell lines that our programme has used for many years to screen potential new drugs because we have a lot of information about these cell lines. For instance, mutations, gene expression, microRNA expression and so on have all been characterised, and this enables us to analyse the cell lines that benefit from a particular combination and potentially identify markers in those cell lines that might also be used as biomarkers in patients."

The researchers have found that some combinations have shown benefit in many cell lines, while others are active in just a few cell lines. When some of the new combinations were tested in human tumours grafted into mice, they were found to be more effective than the most active doses of single drugs.

"These results are promising but we need to repeat and confirm them," said Dr Holbeck. "Our goal is to rapidly translate several novel combinations into clinical trials. There will be many more leads than we can possibly follow through on. Once these data are published, the dataset, and tools to analyse it, will be made available on our web site for all to utilise as they wish.

"To our knowledge this is the first systematic characterisation of approved drugs in a large number of cancer cell lines. We are not making any assumptions about which combinations will give improved activity. The use of many diverse cancer cell lines allows data mining for markers of response that would not be possible with a small set of cell lines.

"Many groups are focusing on 'rational' combinations, i.e. making scientific inferences about which pathways it might make sense to block simultaneously with different drugs. We took a step back, and took an approach that tests all possible drug pairs. This allowed us to test not only the rational combinations, but also to explore drug pairs that otherwise would likely never be tested together."

Professor Stefan Sleijfer, the scientific chair of the EORTC-NCI-AACR Symposium, from Erasmus University Medical Centre (The Netherlands), commented: "This study is interesting because of the use of combinations of drugs already approved and on the market, which were tested in cell lines that have been well characterised in terms of genetic profiles. If confirmed, this study will form a basis for future clinical trials on such combinations in well-defined patient groups."

Contact: Emma Mason
ECCO-the European CanCer Organisation

Related medicine news :

1. Scientists solving the mystery of human consciousness
2. Scientists uncover multiple faces of deadly breast cancer
3. Scientists identify major source of cells defense against oxidative stress
4. Scientists tailor cell surface targeting system to hit organelle ZIP codes
5. Scientists rewrite rulebook on breast cancer in landmark global study
6. Warwick scientists uncover how checkpoint proteins bind chromosomes
7. NIH scientists link quickly spreading gene to Asian MRSA epidemic
8. Joslin scientists identify important mechanism that affects the aging process
9. Scripps Research scientists show how memory B cells stay in class to fight different infections
10. Scientists Map Melanomas Genome
11. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... dropped below 10,000 for the first time since 2011. In 2014, there were 9,967 ... data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Executive Officer Doug Godshall is scheduled to ... Healthcare Conference on December 1, 2015 at 3:00 p.m. ... New York . ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
Breaking Medicine Technology: